Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Operating Leases (2023 - 2026)

ArriVent BioPharma has reported Operating Leases over the past 3 years, most recently at $320000.0 for Q1 2026.

  • Quarterly results put Operating Leases at $320000.0 for Q1 2026, changed N/A from a year ago — trailing twelve months through Mar 2026 was $320000.0 (changed N/A YoY), and the annual figure for FY2024 was $14000.0, down 92.09%.
  • Operating Leases reached $320000.0 in Q1 2026 per AVBP's latest filing, up from $14000.0 in the prior quarter.
  • Across five years, Operating Leases topped out at $320000.0 in Q1 2026 and bottomed at $14000.0 in Q4 2024.
  • Median Operating Leases over the past 3 years was $118000.0 (2024), compared with a mean of $133833.3.
  • Peak annual rise in Operating Leases hit 92.09% in 2024, while the deepest fall reached 92.09% in 2024.
  • Over 3 years, Operating Leases stood at $177000.0 in 2023, then tumbled by 92.09% to $14000.0 in 2024, then surged by 2185.71% to $320000.0 in 2026.
  • Business Quant data shows Operating Leases for AVBP at $320000.0 in Q1 2026, $14000.0 in Q4 2024, and $56000.0 in Q3 2024.